New Drug Approvals in China Reach Record High in 2023
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Address: No.97,Lane 1518,Guangfulin Road,Songjiang District,Shanghai,201620,P.R.China
Tel: 86 2161 026 752
Web: http://www.hoborchem.com/
Shanghai Hobor Chemical Co., Ltd is a production-oriented enterprise dedicated to pharmaceutical intermediates and active pharmaceutical ingredients synthesis and process development,Hobor Chemical has been committed to expedite our customer’s R&D and manufacturing in a time and cost effective manner since 2010 the company started.We focuses on developing efficient process technology for intermediates,active ingredients.
Our R&D lab located in Hi-Tech Park of Shanghai,China,the facility located in Fengxin industrial area,Jiangxi Province,employees experienced chemistry and medicine R&D team and equipped with the state of the art instruments.to be able to complete the low temperature of -80 to 300 high temperature a variety of reactions.Our products are strictly controlled by the LC, NMR,MS ensure customer satisfaction with every batch of products. We have established very good relationship with many global customers since company started.
Custom Synthesis As a innovative research company and active high-tech building block supplier, we are eager to become your professional partner in the following fields:
1. Heterocyclic chemistry and it’s synthetic technology
2. APi’s structure and it’s process research3. Cost effective process for pharma intermediates4. Chiral chemicals realted to above region
We provide Explore new synthetic chemistry Synthesis of novel and/or know compounds Substantial experience in process development, scale up and commercialization Able to follow an entire project, from laboratory to pilot production
QA manager is always involved in working together with our marketing colleage to identify suitable supplier, ensure the quality of products, and control the risks in supply chain.
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
See our Cookie Privacy Policy Here
